Abstract
Objective:
To determine the influence of nasal saline irrigation on Chinese pediatric patients with allergic rhinitis plus asthma.
Methods:
An attempt was made to randomly categorize 60 pediatric patients with allergic rhinitis plus asthma, who were admitted to our hospital (June 2022-March 2023), into 2 groups (n = 30). Participants in the 2 groups were given routine treatment for allergic rhinitis plus asthma, while those in the observation group were additionally administered nasal saline irrigation. Thereafter, the overall effective rate, total adverse reaction rate, nasal sign scores, childhood asthma control test (C-ACT) scores, total nasal symptom scores (TNSS), airway inflammation index (fractional exhaled nitric oxide, FENO), and allergy indices (Total serum IgE, TIgE; eosinophils, EOS) underwent comparative analysis before and after the treatment between the 2 principal groups.
Results:
A significantly escalated overall effective rate was noted in the observation group relative to the control group (P = .023). The lack of a significant difference, particularly in the total adverse reaction rate, was noteworthy between the 2 principal groups (P = 0.640). A comparable analysis of nasal sign scores, C-ACT score, TNSS score, FENO, and allergy indices was conducted between the 2 groups before treatment, which showed a lack of significant differences. Significantly attenuated nasal sign scores, TNSS score, FENO, and allergy indices were observed in the observation group following treatment, relative to both the control group and pre-treatment levels. Significantly elevated C-ACT scores were also noted compared to both the control group and pre-treatment levels (P = .019).
Conclusion:
Nasal saline irrigation proved remarkably effective, particularly in Chinese pediatric patients with allergic rhinitis plus asthma, showing advantages in alleviating disease-related symptoms and signs, reducing airway inflammation, and diminishing the severity of allergic reactions.
Get full access to this article
View all access options for this article.